DWTX News & Events

Dogwood Therapeutics announced it has achieved over 50% of the planned enrollment in its ongoing HAL-CINP-203 Phase 2b chemotherapy induced neuropathic pain, HALT-CINP, trial. HALT-CINP remains on track for top line results to be available during the third quarter of 2026. "If the HALT-CINP study is successful, Halenuron would represent a new therapeutic agent for treating chemotherapy-induced neuropathic pain, a condition for which there are currently no approved therapies. There remains a great need for treatment options for the millions of patients suffering from chemotherapy-induced neuropathic pain and we continue to be encouraged by the rate of enrollment, interim outcomes and safety profile," said Dogwood Therapeutics Chief Medical Officer Michael Gendreau, M.D., Ph.D., "Against a history of failed clinical trials, the ongoing Halneuron(R) clinical trial has the potential to be the first statistically significant trial treating chemotherapy-induced neuropathic pain patients under FDA chronic pain study guidance."

After two consecutive losing session, major indices roared back on Thursday, with strong results out of TSMC bolstering the capex investment theme in semiconductors - semi equipment names such as Applied Materialsand KLA Corpwere some of the strongest performers on the S&P 500.   Sentiment in Financials also rebounded in the wake of broad post-earnings selling in shares of JPMorganand Citias Goldman Sachsand Blackrockrallies on strong Q4 numbers picked up the slack.  Major Regionals like PNC Financialand Regionsare on tap to report results on Friday morning.In the opening hour of the evening session, S&P e-minis and Dow Industrials are sustaining the upward momentum with modest gains, up 0.1%, and Nasdaq 100 is up 0.2%.  In precious metals, Gold and Silver are coiling just below the all-time highs seen earlier this week.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER -Sylvamoup 2.0% after 2026 outlookDOWN AFTER EARNINGS -J.B. Hunt Transportdown 4.3%WaFddown 0.5%ALSO LOWER -QXOdown 4.2% after Q4 pre-announcement, $750M stock offeringDogwood Therapeuticsdown 2.1% after equity offeringJourney Medicaldown 2.0% after equity offeringWoodwarddown 1.5% after announcing winddown of China gas truck business

Dogwood Therapeutics has entered into a securities purchase agreement with a single healthcare-focused institutional investor for up to approximately $12.5 million in gross proceeds through a registered direct offering and a concurrent private placement for the issuance of an aggregate of 4,386,037 shares of common stock, together with warrants to purchase up to an aggregate of 4,386,037 shares of common stock, priced at-the-market under Nasdaq rules. Each share of common stock is being sold together with one warrant to purchase one share of common stock at a combined purchase price of $2.85. The warrants will have an exercise price of $3.28 per share. The warrants will be exercisable upon shareholder approval, and will expire five and one-half years from the effective date of shareholder approval. Upfront gross proceeds from the Offerings are expected to be $12.5 million, before deducting commissions and offering expenses, with the potential for an additional $14.4 million in gross proceeds upon the exercise of the warrants at the election of investors and subject to shareholder approval. The Registered Offering consists of the issuance and sale of 2,338,948 shares of common stock, and the Private Offering consists of the issuance and sale of pre-funded warrants to purchase 2,047,089 shares of common stock and warrants to purchase up to 4,386,037 shares of common stock. Maxim Group LLC is acting as the sole placement agent for the Offerings.